OSTEOGENESIS IMPERFECTA TYPE III
Clinical trials for OSTEOGENESIS IMPERFECTA TYPE III explained in plain language.
Never miss a new study
Get alerted when new OSTEOGENESIS IMPERFECTA TYPE III trials appear
Sign up with your email to follow new studies for OSTEOGENESIS IMPERFECTA TYPE III, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New shot aims to toughen fragile bones in rare disease
Disease control Recruiting nowThis phase 2 trial tests a drug called AGA2115 in 48 Chinese adults and adolescents with osteogenesis imperfecta (types I, III, IV), a condition that makes bones brittle. Participants receive one of three dose schedules by injection under the skin. The study checks for side effec…
Matched conditions: OSTEOGENESIS IMPERFECTA TYPE III
Phase: PHASE2 • Sponsor: Angitia Biopharmaceuticals Guangzhou Limited • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New shot aims to fortify fragile bones in brittle bone disease trial
Disease control Recruiting nowThis study tests a drug called AGA2115 in 80 adults with osteogenesis imperfecta (brittle bone disease) types I, III, or IV. Participants receive either the drug or a placebo as a shot under the skin. The main goal is to see if the drug increases bone density in the spine after 1…
Matched conditions: OSTEOGENESIS IMPERFECTA TYPE III
Phase: PHASE2 • Sponsor: Angitia Incorporated Limited • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC